Skip to content

Psilocybin: all studies

Page 346 of 440: studies 3,451 to 3,460 of 4,400, newest first. Back to the psilocybin overview

Research

Simulation of Non-Ordinary Consciousness

arXiv Preprint Archive March 29, 2025 Khalid M. Saqr preprint

The symbolic architecture of non-ordinary consciousness remains largely unmapped in cognitive science and artificial intelligence. While conventional models prioritize rational coherence, altered states such as those induced by psychedelics reveal distinct symbolic regimes characterized by recursive metaphor, ego dissolution, and semantic destabilization. We present \textit{Glyph}, a generative...

Mycochemical screening, antioxidant, and cytotoxic properties of Panaeolus cyanescens

Nusantara Bioscience March 28, 2025 Khea V. Galay, Sheila Marie Y. Plimaco

Abstract. Galay KV, Plimaco SMY. 2025. Mycochemical screening, antioxidant, and cytotoxic properties of Panaeolus cyanescens. Nusantara Bioscience 17: 137-154. This study focuses on exploring the subtleties of the hallucinogenic mushroom Panaeolus cyanescens Sacc., known for its psychoactive component psilocybin. The study focuses on exploring the phytochemical, antioxidant, and cytotoxic...

Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community

March 27, 2025 Mika Turkia preprint

This retrospective case study features a woman in her mid-50s who spent her childhood in a religious community plagued by sexual abuse of children. She was abused by her father for more than a decade. The church and her mother ignored her reports about it. In her early twenties, she enrolled herself in the Erhard Seminars Training program that destabilized her, inducing a first-onset psychosis,...

DOI: 10.31234/osf.io/mzkyv_v1 (opens in new tab) Ayahuasca Sexual abuse Psychotherapist Clinical psychology +3

Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review.

Journal of Psychosocial Oncology March 26, 2025 Jennifer Bires

Mood disorders and existential distress impact those with cancer or a serious illness at higher rates than the general population. There have been limited pharmacological advances in recent years, and available psychological interventions vary in degree of impact and durability as a treatment modality in this population. A recent renaissance in psychedelic research has suggested that this class...

Exploring factors associated with the intensity of a mystical experience following naturalistic psychedelic use: A retrospective survey.

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025 Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al. 5 citations

The intensity of the psychedelic experience has been hypothesized as the main predictor of response to a psychedelic treatment. This study aimed to investigate factors that may be associated with the intensity of mystical experiences during naturalistic psychedelic use. The data of this comprehensive sample were aggregated from four previous retrospective surveys, where mystical experience...

DOI: 10.1016/j.pnpbp.2025.111300 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Dose intake Mystical experience intensity Mystical experience questionnaire +4

The renaissance of psychedelics in modern psychiatry: a new breakthrough or the myth of a “magic bullet”?

Neurology Bulletin March 15, 2025 V. Skryabin

In recent years, there has been a significant surge of interest in psychedelic research. These studies encompass both neuroscience and their potential clinical applications. This phenomenon, often referred to as the "Psychedelic Renaissance", includes studies on compounds such as psilocybin, MDMA, DMT, and LSD used for the treatment of depression, post-traumatic stress disorder, anxiety, and...

Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.

Journal of Affective Disorders March 15, 2025 Thomas D Meyer, Maya Ibrahim, Lauren N Vale et al. 6 citations

Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic...

DOI: 10.1016/j.jad.2024.12.044 (opens in new tab) Full text (opens in new tab) Psychedelic drugs Behavioral health care Depression research Bipolar disorder +7

Interview with Allen Kalpin and Reiko Ikemoto-Joseph: psychedelics and ISTDP

Journal of Contemporary ISTDP March 14, 2025 Thomas Hesslow

Psychedelic science is growing at a rapid pace, and as evidence accrues, we will most likely see authorization of the use of substances such as psilocybin and MDMA augmenting the effects of psychotherapy in the coming years. Lykos therapeutics (previously called MAPS PBC) recently filed a New Drug Application to the FDA in the US and expects to be able to offer MDMA as a prescribable drug in...

A Machine Learning Using NLP to Predict Long-Term Patient Response

IGI Global eBooks March 13, 2025 K.Suresh Kumar, Sandeep Kumar Davuluri, Lakshman Kumar Kanulla et al. 2 citations

Historical stories and contemporary clinical studies have shown substantial promise for the therapeutic use of psychedelics for the treatment of mood disorders such as depression. Comp360 is COMPASS Pathways' unique synthetic formulation of psilocybin. A recent randomised double-blind phase-II b research showed that it was safe and effective for those with treatment-resistant depression. The...

Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action

Biological Psychiatry March 8, 2025 Jonathan Repple, Maximilian Bayas, Chiara Möser et al. 8 citations

After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression. While several antipsychotics have been investigated for their efficacy in bipolar depression...

DOI: 10.1016/j.biopsych.2025.02.903 (opens in new tab) Mdd #bipolardisorder manic depression Bipolar affective disorder #ketamine ketamine therapy +5